Ferumoxytol + Gadobutrol

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

IC - Interstitial Cystitis

Conditions

IC - Interstitial Cystitis

Trial Timeline

Mar 29, 2023 → May 20, 2025

About Ferumoxytol + Gadobutrol

Ferumoxytol + Gadobutrol is a phase 1 stage product being developed by Lipella Pharmaceuticals for IC - Interstitial Cystitis. The current trial status is completed. This product is registered under clinical trial identifier NCT05811377. Target conditions include IC - Interstitial Cystitis.

What happened to similar drugs?

1 of 5 similar drugs in IC - Interstitial Cystitis were approved

Approved (1) Terminated (2) Active (3)

Hype Score Breakdown

Clinical
6
Activity
8
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05811377Phase 1Completed

Competing Products

20 competing products in IC - Interstitial Cystitis

See all competitors
ProductCompanyStageHype Score
LP-08 80mg + Normal saline + LP-08 20mgLipella PharmaceuticalsPhase 2
25
tacrolimusAstellas PharmaPre-clinical
26
ASP3652 + PlaceboAstellas PharmaPhase 2
35
Mirabegron + PlaceboAstellas PharmaPhase 3
32
TacrolimusAstellas PharmaPhase 2/3
38
ONO-1110 + PlaceboOno PharmaceuticalPhase 2
42
Placebo + JNJ-42160443Johnson & JohnsonPhase 2
27
Pentosan polysulfate sodium 100 mg + Placebo + Pentosan polysulfate sodium 100 mgJohnson & JohnsonApproved
35
BOTOX + Placebo for BOTOXAbbViePhase 2
35
NS-863 Low Dose + NS-863 High DoseNippon ShinyakuPhase 2
42
INS316 solution for inhalation + hypertonic saline 3% sodium chloride solutionMerckPhase 2
27
Abituzumab 1500 mg + Abituzumab 500 mg + PlaceboMerckPhase 2
27
MK-2225 + PlaceboMerckPhase 1
21
Certican® + Neoral + Myfortic + Simulect® + CorticosteroidsNovartisPhase 3
40
Pirfenidone + PlaceboRochePhase 2
35
PD 0299685 at 15mg BID + PD 0299685 at 30mg BID + placebo for PD 0299685PfizerPhase 2
35
Tanezumab + Tanezumab + Tanezumab + TanezumabPfizerPhase 2
27
ERB-041PfizerPre-clinical
18
PF-04383119 + PlaceboPfizerPhase 2
35
AbataceptBristol Myers SquibbPhase 2
42